Wikimedia Creative Commons

Sarepta Therapeutics announced this morning it will sell its rare pediatric disease priority review voucher to Gilead Sciences for $125 million, giving Gilead the rights to have one of its drugs receive fast-track approval from the Food and Drug Administration.

The vouchers let drug companies get a decision on their medicines within six months, rather than the standard 10-plus months. The FDA awarded Sarepta the voucher last year at the same time the agency green-lighted Sarepta's drug that treats Duchenne muscular dystrophy, a move that was controversial at the time because there was disagreement over whether the drug was beneficial. Sarepta still has to conduct a clinical trial to back up the benefits of that drug.

Why this matters: Priority review vouchers have become valuable commodities as drug companies look for ways to jump ahead in the FDA line. There have been a handful of transactions in the decade that vouchers have been around. But Sarepta's $125 million deal fetched a lower price than the two most recent voucher sales of $350 million and $245 million. Analysts at investment bank Leerink Partners thought Sarepta could have gotten at least $200 million, raising questions of whether there is a "broader decline" of interest in the vouchers that command "increasingly astronomical" price tags.

Go deeper

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 11:30 p.m. ET: 30,674,077 — Total deaths: 955,440— Total recoveries: 20,908,811Map.
  2. U.S.: Total confirmed cases as of 11:30 p.m. ET: 6,764,803 — Total deaths: 199,258 — Total recoveries: 2,577,446 — Total tests: 94,211,463Map.
  3. Politics: In reversal, CDC again recommends coronavirus testing for asymptomatic people.
  4. Health: The dwindling chances of eliminating COVID-19.
  5. World: Guatemalan president tests positive for COVID-19 — The countries painting their pandemic recoveries green.
Updated 5 hours ago - Technology

Trump agrees to TikTok deal

Illustration: Sarah Grillo/Axios

President Trump on Saturday said he approved "in concept" a deal whereby TikTok will be allowed to continue operating in the U.S., with Oracle as its "trusted technology partner."

Why it matters: TikTok has nearly 100 million U.S. users, and is still growing fast. Trump has threatened to ban it, due to data privacy concerns related to TikTok's ownership by Chinese tech company.

Updated 6 hours ago - Politics & Policy

Trump says Supreme Court nominee "will be a woman"

President Trump speaking prior to his departure from the White House on Sept. 19. Photo: Sarah Silbiger/Getty Images

President Trump said during a Fayetteville, North Carolina, rally Saturday he'll announce a nominee for Justice Ruth Bader Ginsburg's vacant Supreme Court seat "next week" and "it will be a woman."

Details: Trump told reporters earlier, "The choice of a woman, I would say, would certainly be appropriate."